Transition of visual acuity before initial treatment with neovascular age-related macular degeneration over the past years (A multicenter retrospective study)

Transition of visual acuity before initial treatment with neovascular age-related macular degeneration over the past years (A multicenter retrospective study) - Transition of visual acuity before initial treatment with neovascular age-related macular degeneration over the past years (A multicenter retrospective study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029497

Enrollment

5000

Registered

2017-10-10

Start date

2017-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of age-related macular degeneration with choroidal neovascularization who received photodynamic therapy, intravitreal injections of ranibizumab, aflibercept, pegaptanib, bevacizumab or topical administration of the steroid in the past 10 years (January 1, 2006 to December 31, 2015) and were able to follow more than one year.

Exclusion criteria

Exclusion criteria: Patients have received photodynamic therapy or intravitreal injections of ranibizumab, aflibercept, pegaptanib, or bevacizumab before receiving the initial treatment at each hospital, or patients who refused to participate this study, or patients who are judged to be unfit as the participants of this study.

Design outcomes

Primary

Measure	Time frame
Visual acuity before initial treatment	—

Secondary

Measure	Time frame
Type of initial treatment Visual acuity one year and 2 years after the initial treatment Central subfield retinal thickness before initial treatment, one year and 2 years after the initial treatment	—

Countries

Japan

Contacts

Public ContactTomoko Sawada

Shiga University of Medical Science Department of Ophthalmology

tsawada@belle.shiga-med.ac.jp077-548-2276

Outcome results